ABBVIE

ORIC-944 is an orally bioavailable PRC2 inhibitor designed to improve solubility and stability, with a longer half-life than EZH2 inhibitors. It reprograms AR-independent prostate tumors to AR-dependent states.

Alector presented baseline characteristics for the INVOKE-2 Phase 2 trial of AL002 at AAIC® 2024, a global trial evaluating AL002's safety and efficacy in early Alzheimer’s disease. AL002, a TREM2 agonist, aims to slow disease progression. The trial enrolled 381 participants with early AD, with baseline characteristics confirming the intended population. Treatment-emergent brain MRI changes resembling ARIA were observed, leading to early discontinuation of homozygous APOE e4 carriers. Results are expected in Q4 2024.

AbbVie received a Complete Response Letter from the FDA for ABBV-951, a treatment for motor fluctuations in advanced Parkinson's disease, due to observations during inspection of a third-party manufacturer. The CRL does not raise issues on safety, efficacy, or labeling of ABBV-951.